Search results for "Maladies métaboliques"

showing 3 items of 3 documents

Inflammation et maladies métaboliques : analyse par imagerie du métabolisme des lipoprotéines et lipopolysaccharides au cours de l’inflammation

2021

LPS (lipopolysaccharides) are endotoxins originating from Gram-negative bacteria. They have been extensively described for their ability to interact with and disrupt the intestinal barrier. These toxins are able to cross the gut barrier and to pass into the blood (endotoxemia), leading tolow-grade metabolic inflammation or to a severe inflammatory syndrome (SIRS). Fortunately, some circulating proteins such as PLTP (Phospholipid Transfer Protein) are able to transfer LPS to plasma lipoproteins in order to inactivate and detoxify them.The main goals of this study were to investigate the metabolic fate of LPS from the gut and peritoneal cavity but also the influence of PLTP on these toxins in…

LipopolysaccharidesMaladies métaboliques[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLipoproteinsLipidesLipoprotéineslipids (amino acids peptides and proteins)Metabolic diseasesPltpLipidsIntestin[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyIntestine
researchProduct

Lipopolysaccharides and glucagon-like peptide 1 : from molecular mechanisms to pathophysiology

2016

Obesity and type 2 diabetes are metabolic diseases which have reached epidemic proportions worldwide. These metabolic disorders are related to a low grade inflammation whose molecular origin is still unknown. Previous studies have highlighted the involvement of the gut microbiota and especially components of the cell wall of Gram(-) bacteria: lipopolysaccharides (LPS). We have recently shown that LPS enhance glucagon-like peptide 1 (GLP-1) plasma levels, a hormone which is known to stimulate insulin secretion. Moreover there would be a link between the nutritional qualities of food and LPS plasma levels. Thus diet, LPS and GLP-1 may be closely related. The present work focuses on i) the mol…

[SDV.AEN] Life Sciences [q-bio]/Food and NutritionLPSMaladies métaboliques[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionGut barrierMetabolic diseasesEndotoxémieRégime obésogèneGLP-1Obesogenic dietBarrière intestinale[SDV.AEN]Life Sciences [q-bio]/Food and NutritionEndotoxemia
researchProduct

New insights into the pharmacology of the short-chain free fatty acid receptors 2 and 3

2011

Metabolic diseases, such as diabetes, dyslipidemia or obesity, are more and more weighing on public health expenses in developed countries. Despite active research, these widespread diseases remain difficult to handle. Promising new therapeutic strategies against metabolic diseases include the development of drugs targeting the free fatty acid receptors, as key players in metabolism homeostasis. In this context, the current PhD thesis focuses on the study of two G protein-coupled receptors, namely the short-chain free fatty acid receptors 2 (FFA2) and 3 (FFA3). First, we investigated the expression of the two receptors of interest in a variety of cell types. Then, in order to study the phar…

[SDV.SA]Life Sciences [q-bio]/Agricultural sciencesFree fatty acid receptorsModèle structuralDiabèteShort-chain free fatty acidsPharmacologieRécepteurs couplés aux protéines GG protein coupled receptors[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyObesityObésitéStructural model[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciencesPharmacology[SDV.SA] Life Sciences [q-bio]/Agricultural sciencesSite-directed mutagenesis[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyDiabetesMetabolic diseasesRécepteurs aux acides grasMutagénèse à site dirigéMaladies métaboliquesDyslipidemiaAcides gras à chaîne courte[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidémie
researchProduct